Literature DB >> 27620195

Design and Evaluation of Novel Solid Self-Nanodispersion Delivery System for Andrographolide.

Junnan Xu1, Yueqin Ma2, Yuanbiao Xie1, Yingchong Chen1, Yang Liu1, Pengfei Yue3, Ming Yang1.   

Abstract

Poorly water-soluble drugs offer challenges in developing a formulation product with adequate bioavailability. This study took advantage of the features of nanocrystals and direct compression technologies to develop a novel solid self-nanodispersion delivery system for andrographolide (Andro) in order to increase its dissolution rate for enhancing bioavailability. Andro nanosuspensions (Andro-NS) with a particle size of about 500 nm were prepared by homogenization technology and further converted into dried nanocrystal particles (Andro-NP) via spray-drying. The solid self-nanodispersion delivery system (Andro-SNDS)-loaded Andro-NP was prepared via direct compression technology. The DSC and PXRD results demonstrated that the Andro nanocrystals retained its original crystallinity. The dissolution of the Andro-SNDS formulation was 85.87% in pure water over 30 min, better than those of the coarse Andro and physical mixture of Andro and stabilizer. And the C max (299.32 ± 78.54 ng/mL) and AUC0-∞ (4440.55 ± 764.13 mg/L · h) of the Andro-SNDS formulation were significantly higher (p < 0.05) than those of the crude Andro (77.52 ± 31.73 ng/mL and 1437.79 ± 354.25 mg/L · h). The AUC of the Andro-SNDS was 3.09 times as high as that of the crude Andro. This study illustrated a novel approach to combine the features of nanocrystals and composite particles used to improve oral bioavailability of poorly soluble drug.

Entities:  

Keywords:  andrographolide; bioavailability; nanosuspensions; redispersibility; solid self-nanodispersion delivery system

Mesh:

Substances:

Year:  2016        PMID: 27620195     DOI: 10.1208/s12249-016-0627-7

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  7 in total

Review 1.  Bioavailability Enhancement of Poorly Water-Soluble Drugs via Nanocomposites: Formulation⁻Processing Aspects and Challenges.

Authors:  Anagha Bhakay; Mahbubur Rahman; Rajesh N Dave; Ecevit Bilgili
Journal:  Pharmaceutics       Date:  2018-07-08       Impact factor: 6.321

2.  Novel Luteolin-Loaded Chitosan Decorated Nanoparticles for Brain-Targeting Delivery in a Sporadic Alzheimer's Disease Mouse Model: Focus on Antioxidant, Anti-Inflammatory, and Amyloidogenic Pathways.

Authors:  Haidy Abbas; Nesrine S El Sayed; Nancy Abdel Hamid Abou Youssef; Passent M E Gaafar; Mohamed R Mousa; Ahmed M Fayez; Manal A Elsheikh
Journal:  Pharmaceutics       Date:  2022-05-06       Impact factor: 6.525

3.  Novel nanocrystal-based solid dispersion with high drug loading, enhanced dissolution, and bioavailability of andrographolide.

Authors:  Yueqin Ma; Yang Yang; Jin Xie; Junnan Xu; Pengfei Yue; Ming Yang
Journal:  Int J Nanomedicine       Date:  2018-06-28

4.  Development of Nanoemulsion-based Hydrogel Containing Andrographolide: Physical Properties and Stability Evaluation.

Authors:  Oktavia Indrati; Ronny Martien; Abdul Rohman; Akhmad Kharis Nugroho
Journal:  J Pharm Bioallied Sci       Date:  2020-11-05

5.  Oral Bioavailability Enhancement and Anti-Fatigue Assessment of the Andrographolide Loaded Solid Dispersion.

Authors:  Ching-Chi Yen; Yu-Kai Liang; Chao-Pei Cheng; Mei-Chich Hsu; Yu-Tse Wu
Journal:  Int J Mol Sci       Date:  2020-04-04       Impact factor: 5.923

Review 6.  Antiviral effect of phytochemicals from medicinal plants: Applications and drug delivery strategies.

Authors:  Shimon Ben-Shabat; Ludmila Yarmolinsky; Daniel Porat; Arik Dahan
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

7.  A Brain-Targeted Approach to Ameliorate Memory Disorders in a Sporadic Alzheimer's Disease Mouse Model via Intranasal Luteolin-Loaded Nanobilosomes.

Authors:  Manal A Elsheikh; Yasmin A El-Feky; Majid Mohammad Al-Sawahli; Merhan E Ali; Ahmed M Fayez; Haidy Abbas
Journal:  Pharmaceutics       Date:  2022-03-05       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.